Completed PHASE3 INTERVENTIONAL 1-arm NCT01213017

The Effect of Certolizumab Pegol on MRI Synovitis and Bone Edema in Rheumatoid Arthritis Patients (PICS)

The Effect of Certolizumab Pegol in Combination With Methotrexate on MRI Synovitis and Bone Edema and Patient Reported Outcomes as Measured Using an Automated Visit Manager System in Moderate to Severe Rheumatoid Arthritis Patients

Sponsor: Oklahoma Medical Research Foundation

Conditions Rheumatoid Arthritis

Interventions certolizumab pegol

Updated 7 times since 2017 Last updated: Dec 6, 2017 Started: Sep 30, 2010 Primary completion: Jan 31, 2011 Completion: Apr 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Rheumatoid Arthritis and is currently completed. Oklahoma Medical Research Foundation leads this study, which shows 7 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Dec 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Dec 2017 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Sep 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Oklahoma Medical Research Foundation
UCB Pharma

Data source: Oklahoma Medical Research Foundation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Aventura, United States
• Oklahoma City, United States